Clinical trialPhase 1 / Phase 2Unknown
Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
A Phase I/II Study of Combination Therapy of CG200745 PPA With Gemcitabine and Erlotinib to Determine the Maximum Tolerated Dose (MTD) and Evaluate the Safety and Efficacy for Locally Advanced Unresectable, or Metastatic Pancreatic Cancer
- Outcome
- Outcome unknown
- Phase
- Phase 1 / Phase 2
- Status
- Unknown
- Study type
- Interventional
- Start
- March 2016
- Expected end
- August 2019
- Enrollment
- 24 participants
- Sites
- 1
- Primary outcomes
- Overall Response Rate (ORR)
- Sponsor
- Industry
- Results posted
- No
- Last update
- 17 June 2019
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
\<Part I - Phase I trial\> The phase I clinical trial is to identify the MTD (Maximum Tolerated Dose) and DLT (Dose Limiting Toxicity) of CG200745 PPA in combination use of Gemcitabine and Erlotinib. Initial dose of CG200745 PPA is 187.5 mg/m\^2, and it will be extended to 250 mg/m\^2, 312.5 mg/m\^2 or it will be reduced to 125 mg/m\^2 based on the results of the cohort of 3 subjects per dose level. Based on the 3+3 dose escalation study design, Gemcitabine and Erlotinib are administered as fixed doses, whereas CG200745 PPA is to be administered as in four different cohorts according to the dose level. Each cohort consists of 3 or 6 subjects. \<Part II - Phase II trial\> In the phase II clinical trial, the subjects will be administered with the dose which is to be identified as a recommended dose based on the results of Phase I study. The whole one cycle is consisted of 28 days, same as the phase I. The entire treatment period is 6 cycles and tumor assessment is evaluated every 2 cycles.
Detailed description public domain (ClinicalTrials.gov)
\<Part I - Phase I trial\> The phase I clinical trial is to identify the MTD and DLT of CG200745 PPA in combination use of Gemcitabine and Erlotinib. Initial dose of CG200745 PPA is 187.5 mg/m\^2, and it will be extended to 250 mg/m\^2, 312.5 mg/m\^2 or it will be reduced to 125 mg/m\^2 based on the results of the cohort of 3 subjects per dose level. Based on the 3+3 dose escalation study design, Gemcitabine and Erlotinib are administered as fixed doses, whereas CG200745 PPA is to be administered as in four different cohorts according to the dose level. Each cohort consists of 3 or 6 subjects. * Dose level 0: CG200745 PPA 125 mg/m\^2 puls Gemcitabine 1000 mg/m\^2) and Erlotinib 100 mg * Dose level 1: CG200745 PPA 187.5 mg/m\^2 puls Gemcitabine 1000 mg/m\^2) and Erlotinib 100 mg * Dose level 2: CG200745 PPA 250 mg/m\^2 puls Gemcitabine 1000 mg/m\^2) and Erlotinib 100 mg * Dose level 3: CG200745 PPA 312.5 mg/m\^2 puls Gemcitabine 1000 mg/m\^2) and Erlotinib 100 mg \<Part II - Phase II trial\> In the phase II clinical trial, the subjects will be administered with the dose which is to be identified as a recommended dose based on the results of Phase I study. The whole one cycle is consisted of 28 days, same as the phase I. The entire treatment period is 6 cycles and tumor assessment is evaluated every 2 cycles.